Liquid biopsies for kidney cancer

New research from the Medical University of Graz in Austria in collaboration with Cancer Research UK, Cambridge on the detection of tumour DNA in the blood and urine of kidney cancer patients was published in the journal Genome Medicine last month. The detection of circulating tumour DNA (ctDNA) in blood or urine, known as ‘liquid […]

read more

Research suggests that B cells also play a role in the response to immunotherapy

A recent paper published in the journal Nature earlier this year shed some light on why some patients with soft-tissue sarcoma survived longer than others. The researchers expected that it came down to which patients had the most T cells, an immune cell known to contribute to the success of immunotherapy. However, after studying the […]

read more

ASCO GU Cancers Symposium Highlights 2020

Over 4,000 delegates attended the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco, 13-15 February 2020. The International Kidney Cancer Coalition (IKCC) was present with a booth to raise awareness, and also attended many of the medical and patient advocacy sessions. The past couple of years have been watershed years […]

read more

Scientists develop new technique to ‘listen in’ on cancer cells

A research study published in Nature Methods has uncovered a new technique to ‘listen in’ to how millions of individual cancer cells are communicating with each other in miniature tumours grown in the laboratory. This research is the first time that scientists have been able to analyse the signalling molecules that cancer cells use to […]

read more

Patients ‘left in the dark’ by the NHS over cancer treatments

Macmillan Cancer Support has recently published the results from their annual Cancer Patient Experience Survey, which reveals that around 120,000 cancer patients a year feel that topics, such as treatments and side effects, were not fully explained to them by NHS staff. This made them feel “left in the dark” by the NHS. Thirty-nine percent […]

read more

Integrative oncology: using evidence-based medicine to improve patient outcomes and quality of life

A recent article published in Cancer Therapy Advisor describes what is meant by ‘integrative oncology’ and how evidence based medicine can be used to improve patient outcomes and quality of life. Cancer is among the leading causes of death worldwide, and new cases of cancer may rise to 23.6 million per year by 2030. However, […]

read more

New risk scoring system for metastatic kidney cancer

The treatment options for metastatic renal cell carcinoma (RCC) have changed considerably over the past 10 years with the introduction of immunotherapies, such as nivolumab, ipilimumab and pembrolizumab. However, with the new treatments comes the challenge of selecting the most effective treatment for each individual patient. Clinicians are constantly looking for ways to discover which […]

read more

Cancer vaccine could ‘boost’ immunotherapy effectiveness

A major new study has discovered a means to increase the mutation rate in cancer cells that could create a “powerful vaccine” to boost the effectiveness of immunotherapy. The international study was carried out by scientists at The Institute of Cancer Research, London, the Mayo Clinic in Rochester, US, and the University of Leeds. Using […]

read more

New study shows causes of previously unexplained cancers

An “unprecedented” study has revealed the most comprehensive map of cancer genomes to date. This has enables scientists to discover the genetic causes of some previously unexplained cancers. The research was carried out by an international team involving more than 1,300 scientists and clinicians from 37 countries, who analysed more than 2,600 genomes of 38 […]

read more

Prognosis of type 1 and type 2 papillary renal cell carcinoma

In a recent analysis of a large database, researchers compared baseline clinical/pathological characteristics and survival outcomes of localised type 1 papillary renal cell carcinoma (pRCC) and type 2 pRCC patients. This study, the largest study of localised pRCC published to date, showed that type 2 pRCC patients were more likely to be diagnosed with higher […]

read more
Showing 1 to 10 of 261 results
  TOP